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Application of Biomarkers to Risk
Assessment
by David W. Gaylor,1 Fred F Kadlubar,1 and
Frederick A. Beland1
Due to difficulties in conducting epidemiological studies, most estimates of cancer risk are based on data
from animal bioassays. Extrapolation ofcancer riskestimates in animals to humans requires an assumption
ofequal potency across species based on the average daily dose. The purpose ofthis paper is to examine the
ability to predict tumor incidence across species from DNA adduct concentrations resulting from exposure to
carcinogens. A100-fold range ofstructurally diverse adduct concentrations corresponding to the same tumor
incidence raises questions about quantitative predictability across chemical classes and across species.
Differences in adduct structure, mutagenic efficiency, adduct repair rates, and cellular proliferation could
account for some ofthe differences. For specific carcinogen-DNA adducts, the steady-state levels associated
with a 50% tumor incidence appear to vary over a narrower range. An equal incidence of liver tumors was
obtained at equal concentrations of aflatoxin Bl-DNA adducts for rats and trout. A 2- to 3-fold range of
4-aminobiphenyl-DNA adduct concentrations between mice and dogs appears to be associated with nearly
equal bladder tumor incidence, on the basis of limited data. In humans, a 5-fold higher concentration of a
4-aminobiphenyl-DNA adduct in bladders ofsmokers than ofnonsmokers is compatible with the relative risk
ofbladder cancer due to smoking. DNAadductconcentrations certainly can be usedto improve quantification
of chemical exposures for epidemiological studies. Although promising, more data are needed to judge the
usefulness ofDNA adduct concentrations to predict cancer incidence across species.
Introduction
The estimation ofdisease risk generally involves use of
a dose-response model. The goal is to estimate risk (pro-
portion of adversely affected individuals) as a function of
the dose of the active chemical that reaches the target
tissue. Biologically based dose-response models are gen-
erallybased onthe doseoftheactivechemicalatthetarget
tissue. For example, the Moolgavkar-Venzon-Knudson
(1,2) model ofcarcinogenesis assumes amutagenic change
ofanormalcellto aninitiatedpremalignant state, followed
by proliferation of initiated cells, and finally a mutagenic
change from an initiated state to a malignant state. If
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either one of the mutagenic rates is proportional to the
dose at the targettissue, in the absence of a change in the
cellproliferation rate, theincidence oftumors atlowdoses
is approximately proportional to the dose at the target
tissue. Proportional relationships have been observed
between tumor incidence and DNA adduct concentration
(3), which indicate that DNA adduct concentration can
serve as a biomarker of dose at the target tissue in the
experimental dose range.Anonlinear dose-response rela-
tionship indicates that a chemical affects more than one
mutagenicrate and/oraffectsthe cellproliferation rate.At
the least, use ofthe dose atthe targettissue, as measured
by DNA adduct concentration, removes nonlinearities
introduced by conversion ofthe whole-body administered
dose to the effective dose at the target tissue. In the
absence of pharmacokinetic information, it is generally
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assumed that the dose at the target tissue is directly
proportional tothe dose administeredtothewhole animal.
No doubt, many nonlinear dose-response curves are the
result of the pharmacokinetics involved, even though the
basic mechanism of carcinogenesis may be a linear rela-
tionship between cancer incidence and dose at the target
tissue. Measurement of DNA adduct concentrations may
assistintheelucidation ofcarcinogenic mechanisms andin
the prediction of cancer risk.
Although it is recognized that it is preferable to base
cancer risk estimates on human data, epidemiological
studies are often severely hampered by lack of data on
exposure. Populations under investigation are generally
divided into exposed and unexposed groups on the basis of
occupation, residence, or social habits. Misclassification of
individuals into exposed and unexposed groups weakens
the capacity of an epidemiological study to detect effects.
Quantification of exposure is often not attempted and is
generally limited to years of exposure. Individuals
exposed tohighlevels forshortperiods mayreceive higher
effective doses than individuals exposed to low levels for
longer periods. This bias also weakens the capacity of a
studyto relate riskto dose. Even ifcurrentenvironmental
concentrations of chemicals can be measured, they may
not reflect earlier levels, which may be more pertinent for
cancer risk estimation. The identification and measure-
ment ofmolecular biomarkers in individuals will certainly
increase the number and type of epidemiological studies
that can be conducted by better identifying exposed indi-
viduals andbyprovidinginformation on dose forquantita-
tive risk estimation. Furthermore, molecular biomarkers
that are related to disease end points can be used to
identify individuals who may be at higher risk because of
inherent genetic factors or lifestyles.
Tumor Incidence Prediction from DNA
Adduct Concentration
Beland and Poirier (4) provided a list of DNA adduct
concentrations corresponding to 50% tumor incidence
induced in animals by several carcinogens (Table 1). The
100-fold range of DNA adduct concentrations associated
with the same tumor incidence raises questions about
predicting tumor induction potential on the basis ofDNA
adduct levels across species. Some ofthe differences may
be due to nongenotoxic promotional effects (e.g., cell pro-
liferation rate) of carcinogens. For example, there is a
nearlylinearrelationshipbetween livertumorincidencein
mice and DNA adduct concentration with 2-acetyl-
aminofluorene (3); however, therelationshipbetweenblad-
der tumor incidence and DNA adduct concentration with
2-acetylaminofluorene is highly nonlinear. Cohen and Ell-
wein (7) attribute this nonlinearity to the proliferative
cellular effects of 2-acetylaminofluorene on the mouse
bladder. Other differences in DNA adduct concentrations
associated with identical tumor incidences may be due to
differences in repair rates. The observation that identical
levels of aflatoxin B1-DNA adducts in rats and rainbow
trout correspond to the same incidence ofliver tumors (8)
indicates that it may be possible in some cases to make
comparisons across species.
Talaskaetal. (6) observedthatadministration of4-amino-
biphenyl (4-ABP) at doses that produced urinary bladder
tumors in 20 out of24 dogs induced average steady-state
levels of100 fmole 4-ABP adduct/,Lg ofDNA. In Table 1, a
level of 150 fmole adduct/V±g DNA corresponds to a 50%
incidence ofurinary bladder tumors in mice. The ultimate
question is whether DNA adduct concentrations in
humans could beused to predict cancerrisk. Talaskaetal.
(9) observed an average of only 0.05 fmole of N-(deoxy-
guanosin-8-yl)-4-aminobiphenyV,ug DNA in the bladder
of13 smokers. Other aromatic amine adducts may also be
associated with bladder tumors in humans. The total
4-ABP adduct concentration in the 13 smokers averaged
0.27 fmole/,ug DNA. Smokers have a 2- to 10-fold in-
creased risk overnonsmokers for developing bladder cancer
(10). At arelative risk of4.0, the incidence ofbladder tumors
inmalesmokersisestimatedtobeabout0.04. Intheabsence
ofdata,ifbladder cancerincidenceisproportionalto4-ABP-
DNAadductconcentration,theconcentration corresponding
to a 50% bladder tumorincidence in males can be estimated
to be 0.27 x (0.50/0.04) = 3.4 fmole 4-ABP adduct/p.g
DNA. This is well below the concentration of 150 fmole
4-ABP adduct/p.g DNA associated with a 50% incidence of
Table 1. DNA adduct levels in experimental animals associated with a 50% tumor incidence.a
Carcinogen Species Tissues DNA adduct Adduct level, pmole/mg
MNU Mice Bone, thymus 06-Me-dG 220
ENU Mice Bone, thymus 06-Et-dG 25
NDEA Rats Liver 04-Et-dT 2
AFB1 Rats Liver N7-AFB,-dG 3
Trout Liver N7-AFB,-dG 3
2-AAF Mice Liver C8-AF-dG 110
Mice Urinary bladder C8-AF-dG 250
4-ABP Mice Liver C8-ABP-dG 250
Mice Urinary bladder C8-ABP-dG 150
Dogsb Urinary bladder C8-ABP-dG lOOc
Abbreviations: MNU,N-methyl-N-nitrosourea; ENU,N-ethyl-N-nitrosourea; NDEA,N-nitrosodiethylamine; AFB1, aflatoxin B1; 2-AAF,2-acetyl-
aminofluorene; 4-ABP, 4-aminobiphenyl; 06-Me-dG, 06-methyldeoxyguanosine; 06-Et-dG, 06-ethyldeoxyguanosine; 04-Et-dT, 04-ethyldeoxy-
thymidine;N7-AFB,-dG, trans-8,9-dihydro-8-(deoxyguanosin-7-yl)-9-hydroxyaflatoxin B1; C8-AF-dG, N-(deoxyguanosin-8-yl)-2-aminofluorene; C8-
ABP-dG, N-(deoxyguanosin-8-yl)-4-aminobiphenyl.
aAdapted from Beland and Poirier (4).
bBladder tumors in 20 out of24 dogs (5).
cFromlTlaska et al. (6).
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urinarybladdertumorsinmice; however, otheradductsmay
be associatedwith urinarybladder tumors in humans. Mea-
surements in humans indicate that 4-ABP adducts account
for 10.6% oftotal smoking-related adducts. Ifonly 10.6% of
human bladder cancer is associated with 4-ABP adducts,
then the concentration in humans corresponding to a 50%
incidence canbeestimatedtobe3.4 x (100/10.6) = 32fmole
4-ABP adductVLg DNA, which is nearer to the concentra-
tions observedfordogs andmice Thesecalculations assume
a linear relationship between blat ler tumor incidence and
4-ABP adduct concentration in humans.
Talaska et al. (9) observed an average of 0.01 fmole of
N-(deoxyguanosin-8-yl)-4-aminobiphenyVl>g DNA in the
bladders of29nonsmokers. Therelative adductconcentra-
tion of smokers to nonsmokers, 0.05/0.01 = 5, provides a
relative risk well within the range of that for bladder
cancer among U.S. males. Even if adduct concentrations
cannot be used to estimate absolute cancer risks, relative
adduct concentrations may be useful for estimating rela-
tive cancer risks.
Conclusions
Too few data exist at this time to judge the capacity of
DNA adduct concentrations to predict cancer incidence
across species. Cross-species comparisons of aflatoxin B1
liveradducts and4-ABPbladderadducts areencouraging;
however, differences in adductrepair rates and the effects
ofcarcinogens on cellular proliferation complicate predic-
tion of cancer incidence. The ratio of the average con-
centration of N-(deoxyguanosin-8-yl)-4-aminobiphenyl in
the bladders ofmale smokers compared to nonsmokers is
similar to the relative risk forbladder cancer among male
smokers. Data on DNA adduct concentrations and tumor
incidence in different species, involving more carcinogens,
are required before it will be apparent if useful patterns
are emerging for cancer risk estimation. Certainly, DNA
adduct concentrations canbeused to quantifyexposure to
chemical carcinogens.
This manuscript was presented at the Conference on Biomonitoring
and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
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